130.21 USD
↘ 1.07 (0.82%)AT CLOSE (11:59 AM EDT)
Gilead Sciences Inc
GILDNASDAQ • USD
131.60
↗ 1.39 (1.06%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
131.60
↗ 1.39 (1.06%)
Market: CLOSED
Gilead Sciences Inc (GILD) trades at $130.21 per share. The stock presents a mixed profile: our models indicate a Strong Buy for underlying fundamentals, while technical indicators flash a Strong Sell. Notable factors include a robust Altman Z-Score, a strong Piotroski F-Score of 7/9, exceptional Return on Equity (39.2%) and a bearish Death Cross on the long-term moving averages. Valuation metrics place GILD at a fair price relative to peers.
Technical & fundamental data as of Jul 31, 2026.
Open?$130.23
High?$130.89
Low?$128.76
Prev. Close?$131.28
Volume?6.5M
Avg. Volume?7.5M
VWAP?$130.14
Rel. Volume?0.86x
Bid / Ask
Bid?$123.02 × 100
Ask?$139.48 × 100
Spread?$16.46
Midpoint?$131.25
Valuation & Ratios
Market Cap?161.7B
Shares Out?1.2B
Float?926.2M
Float %?74.6%
P/E Ratio?17.54
P/B Ratio?6.87
EPS?$7.42
Dividend?2.49%
Ex-Dividend?N/A
News
Profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Themes
Employees
17.0K
Market Cap
161.7B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1992-01-22
Address
333 LAKESIDE DR
FOSTER CITY, CA 94404
Phone: (650) 574-3000
FOSTER CITY, CA 94404
Phone: (650) 574-3000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookStrong Buy
Strong SellNeutralStrong Buy
F-Score?88
Z-Score?97
Momentum?83
Short Sent.?78
Piotroski F-Score?7/9Strong
Altman Z-Score?4.64Safe
Confidence?81%High
Short InterestModerate
Short % of Float?2.73%Low
Short Interest?25.3M
Days to Cover?3.7
Free Float926.2M
Avg Daily Volume6.9M
Settlement Date2026-07-15
Financial Health
Current Ratio?1.97Adequate
Quick Ratio?1.77Adequate
Cash Ratio?0.80Adequate
Debt/Equity?0.94Moderate
ValuationFAIRLY VALUEDvs 9 peers + S&P 500
Score78/100
P/E?17.5CHEAP▾
Peers100
S&P73
P/B?6.87FAIR▾
Peers33
S&P27
P/S?5.44FAIR▾
Peers70
S&P26
P/FCF?15.8CHEAP▾
Peers88
S&P71
EV/EBITDA?12.1FAIR▾
Peers88
S&P68
EV/Sales?5.93FAIR▾
Peers70
S&P28
Returns & Efficiency
ROE?39.2%STRONG▾
Peers86
S&P87
ROA?16.4%STRONG▾
Peers88
S&P90
Cash Flow & Enterprise
FCF?$10.2B
Enterprise Value?$176.2B
Fundamentals ratios updated end of day